Todd Zion PhD

Todd C. Zion, PhD founded SmartCells, Inc. in 2003 to develop SmartInsulin™, the first glucose-regulated, injectable formulation for treating diabetes. As SmartCells’ President and CEO, Todd was instrumental in raising $10M in equity financing from individual investors and $10M in grants to support research and clinical development. In December 2010, Merck and Co. acquired SmartCells for over $500M in cash and clinical milestone payments.

Dr Zion developed the SmartInsulin™ technology as part of his doctoral thesis work in Chemical Engineering at the Massachusetts Institute of Technology. Prior to enrolling at MIT, he worked as a polymer development engineer at Eastman Kodak. Todd graduated from Cornell University summa cum laude with a B.S. in Chemical Engineering.

Dr Zion now enjoys advising technology entrepreneurs through MIT’s Venture Mentoring Service. He also serves on a number of advisory boards including those of the Beth Israel Deaconess Medical Center, Joslin Diabetes Center, and the Cornell Engineering College Council.